Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1Phase 2 1Phase 1 1

Status

Unknown 17Recruiting 5Active not recruiting 4Withdrawn 3Terminated 3Not yet recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Pelvic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Immunotherapy, Adoptive × Clear all
NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Capital Medical University

Phase 1/2 Completed
40 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡